Joshua Linscott, MD, PhD

Associations

• Genitourinary Oncology
• Molecular Medicine Program

Dr. Linscott is a translational researcher focused on urothelial carcinoma, with a particular interest in the discovery and development of urinary cell-free DNA biomarkers. Dr. Linscott’s research goals include defining patterns of urinary cell-free DNA methylation as predictors of treatment response and disease progression, as well as studying the tumor immune microenvironment in BCG-treated patients using spatial transcriptomics.

• Chatzkel J, Linscott J, Daniel Grass G, Li R. Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies. Eur Urol Focus. 2025 Jul. Pubmedid: 40716995.
• Guske C, Immen N, Conant D, Laborde J, Linscott J, Hayes M, Jazayeri SB, Fazili A, Siegel E, Dessureault S, Sanchez J, Stefanou A, Manley B, Felder S. Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer. Cancer Control. 2025 Jan.32. Pubmedid: 39848249. Pmcid: PMC11758541.
• Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. FGFR Inhibition in Urothelial Carcinoma. Eur Urol. 2025 Feb.87(2):110-122. Pubmedid: 39353825.
• Guske C, Jazayeri SB, Harrs C, Rao N, Davaro F, Xu H, Zemp L, Yu A, Gilbert SM, Poch M, Spiess PE, Sexton W, Linscott J, Li R. Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025 Aug.8(4):888-892. Pubmedid: 40670271.
• Linscott J, Li R. Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Oct.212(4):624-625. Pubmedid: 38912644.
• Linscott JA, Miyagi H, Murthy PB, Yao S, Grass GD, Vosoughi A, Xu H, Wang X, Yu X, Yu A, Zemp L, Gilbert SM, Poch MA, Sexton WJ, Spiess PE, Li R. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer. Curr Oncol Rep. 2024 Aug.26(8):945-958. Pubmedid: 38837106.
• Linscott JA, Meeks JJ, Dyrskjøt L, Li R. The Elusive Horizon: Biomarkers in Urothelial Carcinoma. Eur Urol. 2024 Apr.85(4):317-319. Pubmedid: 38278663.
• Linscott JA, Sexton WJ. Editorial Comment. J Urol. 2024 Apr.211(4):573-574. Pubmedid: 38241201.

• Title: Utilizing Cell Free DNA to Detect Minimal Residual Disease and Monitor Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
  Award Number:
  Sponsor: American Urological Association (AUA)
  Linscott, J. (PD/PI)